Clinical trials: Amyotrophic Lateral Sclerosis (ALS), open to volunteers
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Tongue-strengthening Exercises in People With ALS.
This study is testing a tongue exercise program for people living with ALS to see if it can help support speech and swallowing. All participants will receive the treatment, and researchers will measure changes over time by…
- Trial name
- NCT07295990
- Testing
- Isometric Lingual Strength Exercises
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Digital Speech Markers for Monitoring ALS in Spanish Speakers
The goal of this observational study is to learn how speech and breathing change over time in Spanish-speaking individuals with amyotrophic lateral sclerosis (ALS) compared to age- and gender-matched individuals without ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
- Trial name
- NCT07341334
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07743268
- Testing
- nL-TARDB-006
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- n-Lorem Foundation
Amyotrophic Lateral Sclerosis, ALS
Multicenter ALS Imaging Study
This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year.
- Trial name
- NCT06735014
- Testing
- Magnetic Resonance Imaging, Plasma neurofilament light chain (NfL) quantification
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Minnesota
Amyotrophic Lateral Sclerosis (ALS)
Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis
The goal of this clinical trial is to determine whether lung insufflation capacity (LIC) training can help maintain respiratory function and prolong tracheostomy-free survival in people with amyotrophic lateral sclerosis (ALS).
- Trial name
- LIC-ALS (NCT07257302)
- Testing
- LIC Trainer (Lung Insufflation Capacity Trainer)
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- National Center of Neurology and Psychiatry, Japan
ALS (Amyotrophic Lateral Sclerosis)
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited.
- Trial name
- UNZUELUZON ALS (NCT07737977)
- Testing
- peripheral venous blood collection, collection of medical data related to patient care
- Where
- 2 sites in France, Spain
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Amyotrophic Lateral Sclerosis (ALS)
Safety Study of XT-150 in Participants With ALS
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT06704347
- Testing
- XT-150
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Xalud Therapeutics, Inc.
ALS, ALS (Amyotrophic Lateral Sclerosis)
Healey ALS MyMatch Common Screening Protocol
The goal of the Healey ALS MyMatch Common Screening Protocol (MCSP), an observational study, is to identify individuals with ALS who may be eligible to be matched to a currently enrolling ALS MyMatch trial.
- Conditions
- ALS, ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
- Trial name
- MCSP (NCT07400393)
- Volunteers
- 500 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis (ALS), Autoantibody
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Autoantibody, Plasmapheresis
- Trial name
- PALADIN2 (NCT07726563)
- Testing
- plasmapheresis
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Amyotrophic Lateral Sclerosis (ALS)
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using…
- Trial name
- NCT07142291
- Testing
- Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg)
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 105 people
- Sponsor
- PhenoNet, Inc.
Amyotrophic Lateral Sclerosis (ALS)
HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality.
- Trial name
- tDCS-ALS (NCT06719947)
- Testing
- Active HD-tDCS, Simulated HD-tDCS
- Where
- 4 sites in Brazil, Chile
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Rio Grande do Norte
Amyotrophic Lateral Sclerosis (ALS), Neurodegenerative Disorders
Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease, often difficult to diagnose due to symptoms similar to other neurological pathologies.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Neurodegenerative Disorders, Motor Neuron Diseases
- Trial name
- DIAGONALS (NCT07706270)
- Testing
- Serum Neurofilament Serum NfL Measurement
- Volunteers
- 138 people
- Sponsor
- University Hospital, Montpellier
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07703462
- Testing
- nL-TARDB-002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis)
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)
Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment.
- Trial name
- SpeechBCI (NCT07698496)
- Testing
- Chronic speech BCI
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Grenoble
Amyotrophic Lateral Sclerosis ALS
Intestinal Microbiome Transplant in ALS
This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected.
- Trial name
- NCT07017946
- Testing
- MTP-101C
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis (ALS)
Identification of Early Markers for ALS
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available.
- Trial name
- PremodiALS (NCT07213440)
- Testing
- lumbar puncture
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure
A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease Patients, Neuromuscular Disease
- Trial name
- EVENT ALS (NCT07071935)
- Testing
- Non-invasive ventilation
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Pennsylvania